PARIS Johnson & Johnson signed a definitive agreement to acquire all of the assets of Tibotec-Virco NV for $320 million in cash and debt. (BioWorld International)

Amrad’s Stock Falls On Poor Phase II Results For Emfilermin

By Mark Lawson

Wednesday, March 27, 2002

Buy Reprint

No Abstract

New Gene Inhibition Technique Aims To Hasten Gene Analysis

By Sharon Kingman

Wednesday, March 27, 2002

Buy Reprint

No Abstract

Schering To Purchase Collateral For $140M In Stock Exchange

By Rainer B. Langen

Wednesday, March 27, 2002

Buy Reprint

No Abstract

Millennium, Compugen In Deal For Protein Pathway Software

By Rachelle H.B. Fishman

Wednesday, March 27, 2002

Buy Reprint

No Abstract

BioWorld

Store

Others

BioWorld-International-2002-03-27

Avidex Platform Creates TCRs; Company Planning Partnerships

U.S. Research Foundation Backs Swedish Stem Cell Program

ReGen’s Phase IIa Interim Data Not Significant In Alzheimer’s

Other News To Note

Vernalis Seeks Second Nasdaq Listing, Reports Profitability

J&J Buying Tibotec-Virco For $320 In Cash And Debt

Amrad’s Stock Falls On Poor Phase II Results For Emfilermin

New Gene Inhibition Technique Aims To Hasten Gene Analysis

Schering To Purchase Collateral For $140M In Stock Exchange

Millennium, Compugen In Deal For Protein Pathway Software

Explore BioWorld.com

BioWorld

Store

Others

Login to Your Account

BioWorld

Store

Others

BioWorld-International-2002-03-27

Explore BioWorld.com

BioWorld

Store

Others